Rat Models of Corneal Neovascularization in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Corneal Neovascularization

Corneal neovascularization is the abnormal growth of new blood vessels from the limbus into the normally avascular corneal stroma. A healthy cornea maintains its transparency and remains free of blood vessels through several natural anti-angiogenic mechanisms.

These protective mechanisms include soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), which binds VEGF-A, along with thrombospondins, pigment epithelium-derived factor (PEDF), and endostatin. Disruption of these mechanisms can lead to pathological corneal angiogenesis.

Common causes of corneal neovascularization include:

• Infection and corneal inflammation
• Hypoxia
• Chemical or thermal injury
• Surgical trauma, including corneal sutures
• Damage to the limbal barrier

New blood vessel growth may also be accompanied by lymphangiogenesis. Together, these changes can reduce corneal transparency, compromise ocular immune privilege, and increase the risk of corneal transplant rejection.

Corneal Neovascularization in Experimental Research

The cornea provides a useful experimental model for studying angiogenesis, inflammation, vascular growth, and anti-angiogenic therapies.

Because the normal cornea is transparent and avascular, researchers can induce neovascularization at a defined location and time, then monitor the development and regression of new vessels in the living eye.

Common experimental approaches include corneal sutures, stromal micropockets, implanted pellets, and injury-induced models. These methods allow researchers to investigate disease mechanisms and evaluate the effects of pro-angiogenic or anti-angiogenic compounds.

Animal models of corneal neovascularization generally serve two purposes:

• Disease modeling: Investigating the onset, progression, and treatment of corneal neovascularization.
• Angiogenesis assessment: Measuring vascular responses to experimental compounds, including therapies intended for other tissues.

Non-invasive, longitudinal imaging makes it possible to measure vessel growth, vascularized area, and treatment response over time, reducing the need for repeated tissue collection.

However, animal models do not fully reproduce human clinical outcomes. Visual impairment, long-term corneal graft survival, and chronic disease progression require clinical evaluation. Anatomical differences between rodent and human corneas, including corneal thickness and the distance from the limbus to the visual axis, must also be considered when interpreting vessel growth and regression.

Rat Models of Corneal Neovascularization

The rat offers a larger eye than the mouse while remaining a small-animal model, which eases injection and imaging without moving to a large species.

Published MICRON Research: Corneal Neovascularization in Rats

This page lists 4 papers from the MICRON literature, published 2014 to 2022, that study corneal neovascularization in rats.

Of these publications:

• 4 studies used rats as the primary corneal neovascularization disease model.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published corneal neovascularization research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Fundus Fluorescein Angiography

Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.

This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Which MICRON systems and add-ons appear?

Which strains and genetic lines are used?

Which other species appear alongside?

What other conditions are recorded on the same papers?

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

The papers

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.